focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Why they have put the SP in the hands of these clowns is completely beyond reason / the amounts are correct 6mill (with tax credits) they are in the right ball park to see us through but we know a raise should of been easy and oversubscribed for 4mill / ...........
Of course we have a lot of interested parties in discussions to license our CHK1
SRA737+LDG in Anogenital Cancer: Potential Registration-Intent Phase 2 Trial.
Very promising anogenital cancer signal.
Anogenital cancer: tractable opportunity to potentially pursue registration-intent studies.
Unmet medical need
Substantial potential market opportunity
https://s28.q4cdn.com/726829854/files/doc_downloads/events/ASCO-SRA737-Analyst-Call-Presentation_final.pdf
That’s before you look at combination therapies even paediatrics take a look at ACCELERATE and look at the companies involved: https://www.ejcancer.com/article/S0959-8049(23)00302-7/fulltext
CHK1 inhibitors have demonstrated activity in desmoplastic small round cell tumours and have a potential role in the treatment of other paediatric malignancies, such as neuroblastoma and Ewing sarcoma. Access to CHK1 inhibitors for paediatric clinical trials is a high priority.
A good SDC-1801 first 3 cohorts update should see this start to take off, it will open the gates for II’s/HNWI’s/Funding/License Deals/TO’s with the added benefit of SRA737 license deal possibly close its all systems go. You’ve only got to look at some of the Brepocitinib data that we have the potential to match/beat to see where this is potentially going….
Pfizers/Priovant Brepocitinib a dual inhibitor of TYK2 and JAK1, is expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases, as compared to agents that inhibit either TYK2 or JAK1 alone.
Brepocitinib has been evaluated in 14 completed Phase 1 and Phase 2 studies, including five placebo-controlled Phase 2 studies in psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata, and hidradenitis suppurativa. All five of these placebo-controlled Phase 2 studies generated statistically significant and clinically meaningful results. Oral brepocitinib’s safety database includes over 1,000 exposed subjects.
A large, global Phase 2b study in Lupus (SLE), designed to serve as one of two registrational studies is expected to generate top-line results in the second half of 2023……
Biohaven reported first dosing of their P1 TYK2/JAK1 on the 31/05 could have been up to 2 weeks prior and updated yesterday on the first 3 cohorts so 8 - 10 weeks. Good to see well tolerated and only mild adverse events / expecting to see excellent first 3 cohort data on SDC-1801 it’s what they have worked towards tweaking safety first…. Not long now an excellent update should blow the roof off…
P1 start date it's close ...
Biohaven has now successfully dosed three dose cohorts with single ascending doses of its brain penetrant TYK2/JAK1 The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data that are available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported.
Concerning they are looking at other countries for regulatory approval they must be concerned it may be rejected on the part of the pre-clinical data that needs additional review.
What other countries would give regulatory approval if the UK rejects it?
At present, cars confirmed for the test track include Tesla’s Model 3 along with a selection of new EVs from Mercedes-Benz, Nissan, Renault and Mazda, with more examples to be added.
Furthermore, the cars will be charged in a zero-emission way, too. AFC Energy will be providing an off-grid, rapid EV charger using its HydroX-Cell H-Power EV Recharge system -the first in commercialised off-grid hydrogen fuelled EV recharging that offers a solution to infrastructure where conventional charging is unavailable.
https://www.themotoringdiary.com/2021/06/come-and-try-out-the-latest-evs-at-the-british-motor-show/
Business confidence has jumped to its highest level in 16 years as Britain prepares to exit the coronavirus lockdown.
https://www.theguardian.com/business/2021/jul/12/uk-business-confidence-jumps-ahead-of-19-july-lockdown-lifting